CRISPR | CHOP Research Institute
 

CRISPR

Researchers Tap Into T Cells’ Natural Biology to Help Boost CAR T-Cell Therapy

Published on
Apr 10, 2024
in Cornerstone Blog
FOXO1 Protein Helps CAR T-cell Longevity, Effectiveness
Evan Weber, PhD, and a research team from CHOP and Stanford Medicine discovered that the protein FOXO1 plays a key role in regulating CAR T cells’ longevity and effectiveness.

CHOP Researchers Study Base-editing Therapies for Three Genetic Diseases of Newborns

Published on
Feb 28, 2024
in Cornerstone Blog
Researchers Study Ways to Target Genetic Diseases of Newborns
William Peranteau, MD, along with CHOP and Penn researchers are developing “one-and-done” new base-editing therapies for three genetic diseases of newborns.

First Two Gene Therapies for Sickle Cell Disease Supported by CHOP Clinical Research

Published on
Jan 3, 2024
in Cornerstone Blog
Two Gene Therapies Tested at CHOP Approved for Sickle Cell Disease
After decades of limited progress in treating sickle cell disease, we have reached an historical moment with two new gene therapies.

AHQR Award, Penn Medicine Awards, $1.3 Million Donation, PKU, Cardiac Arrest

Published on
Nov 10, 2023
in Cornerstone Blog
In The News: AHQR Award, Penn Medicine Awards, $1.3 Million Donation
This week’s research news features awards for furthering patient-centered outcomes research careers and for recognizing the importance of mentorship.

Community-Driven Research, CRISPR, RNA Sequencing, Cover of the Year

Published on
Feb 3, 2023
in Cornerstone Blog
In the News
In this news roundup, we celebrate research tools new and old, from RNA sequencing to gene editing to the best tool of all: collaboration.

Featured Research, Tonsillectomy, Gene Therapy, CAR T-Cell Therapy

Published on
Jun 24, 2022
in Cornerstone Blog
In the News
This week’s In the News features endocrinology research, news on gene therapy in blood disorders, CAR T-cell therapy, and more.

“Encourage Diversity of Thought:” Q&A With Marco Carpenter, PhD, Diversity Fellow

Published on
Dec 20, 2021
in Cornerstone Blog
Q&A With Marco D. Carpenter, PhD, Diversity Fellow
Dr. Carpenter’s research seeks to better understand how environmental factors affect the origins of disease via epigenetic modifications.
Will Bailis, PhD
Will Bailis

Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.

E-mail:
bailisw [at] chop.edu

What is PU.MA, a New Disease Discovered by CHOP Scientists?

Published on
May 24, 2021
in Cornerstone Blog
Snapshot Science: What is PU.MA?
A previously unreported immunodeficiency disease prevents the formation of the B cells and antibodies that help fight off infections.

Shalem Laboratory

Shalem Lab

The lab focuses on translational target discovery for a range of neurodegenerative diseases. We combine technology development of large-scale CRISPR-based perturbation screens with application of such technology together with additional genomic approaches.